The peculiarities of adiponectin and resistin interrelationships with the components of metabolic syndrome in patients with coronary heart disease and concomitant nonalcoholic fatty liver disease
DOI:
https://doi.org/10.14739/2310-1210.2016.5.82568Keywords:
Coronary Artery Disease, Non-Alcoholic Fatty Liver Disease, Adiponectin, Resistin, Metabolic SyndromeAbstract
Objective: to investigate the interrelationships between adiponectin and resistin levels with the components of metabolic syndrome in patients with coronary heart disease and concomitant nonalcoholic fatty liver disease.
Methods. Cross-cohort analytical study involved 46 patients, the primarily selected group consisted of 24 patients, mean age 58 y (44.64) with documented coronary artery disease, stable exertional angina of II–III functional class combined with NAFLD; comparison selected group: 20 patients, mean age was 60.5 y (50.5; 65) with coronary artery disease without NAFLD. The control selected group consisted of 12 healthy individuals.
Results: a significant increase in the value of BMI by 13 % (p<0.05), triglyceride levels by 36 % (p<0.05) were observed in patients with coronary artery disease and NAFLD, there was valid (p<0.05) increase in insulin levels compared to healthy individuals (4.75 times) and CHD patients without structural and functional changes in the liver (in 2.42 times). HOMA index levels were 5 times higher in comparison to healthy people and 2.35 times higher compared to patients with CHD (p<0.05). The adiponectin serum level in patients with coronary heart disease and NAFLD was 60 % lower than among healthy individuals (p<0.05), and 31.6 % (p<0.05) than in the comparison group, while the level of resistin was 48 % higher in patients of the primarily selected group compared to the control selected group, and 27 % higher than in the comparison selected group (p˂0.05).
Conclusions: patients with CHD associated with the nonalcoholic fatty liver disease are characterized by adipocytokine imbalance: the reduction of the adiponectin concentration and the elevation of the resistin levels if compared to the control selected group and CHD patients without liver disease. In patients with CHD combined with NAFLD, were determined multi-directional correlative interrelationships of adiponectin and resistin with components of metabolic syndrome, thus indicating pathogenesis links of found violations.
References
Horbas, I. M. (2010). Otsinka poshyrenosti ta kontroliu faktoriv ryzyku sertsevo-sudynnykh zakhvoriuvan sered naselennia ta likariv [Evaluation of prevalence and control of risk factors for cardiovascular disease in the population and doctors]. Liky Ukrainy, 1, 4–9. [in Ukrainian].
Serkova, V. К., Kobrynchuk, Y. L., & Romanova, V. A. (2011). Leptin u bol'nykh ishemicheskoj bolezn'yu serdca v sochetanii s sakharnym diabetom [Leptin in patients with coronary heart disease combined with diabetes]. Ukrainskyi kardiolohichnyi zhurnal, 3, 19–23. [in Ukrainian].
Knight, J. A. (2011). Diseases and Disorders Associated with Excess Body Weight. Annals of Clinical & Laboratory Science, 41(2), 107–140.
Serediuk, N. М., & Vatseba, M. O. (2013). Rol markeriv symtemnoi imunozapalnoi aktyvatsii, leptynu ta adyponektynu u perebihu esentsialnoi arterialnoi hipertenzii v poiednanni z ishemichnoiu khvoroboiu sertsia, ozhyrinniam ta podahroiu [Role of markers of systemic immunoinflammatory activation, leptin and adiponectin in the course of essential hypertension in combination with ischemic heart disease, obesity and gout]. Aktualni problemy suchasnoi medytsyny, 13(3), 260–263. [in Ukrainian].
Fadeenko, G. D., Solomenceva, T. A., Dovganyuk, I. E´., & Sytnik, K. A. (2014). Rannie priznaki ateroskleroza u bol'nykh s nealkogol'noj zhirovoj bolezn'yu pecheni [The early signs of atherosclerosis in patients with nonalcoholic fatty liver disease]. Suchasna hastroenterolohiia, 4(78), 32–37. [in Ukrainian].
Balukova, E. V., Baryshnikova, N. V. ,& Belousova, L. N. (2016). Nealkogol'naya zhirovaya bolezn' pecheni: sovremennoye sostoyaniye problemy [Nonalcoholic fatty liver disease: state of the art]. Farmateka, 2, 63–68. [in Russian].
Vdovychenko, V. І., & Aksentiychuk, H. B. (2013). Poshyrenist nealkoholnoi zhyrovoi khvoroby pechinky sered pomerlykh, yaki strazhdaly na tsukrovyi diabet 2 typu [Prevalence of nonalcoholic fatty liver disease among the dead, who suffered from type 2 diabetes mellitus]. Suchasna hastroenterolohiia, 1(69), 41–46. [in Ukrainian].
Corey, K., & Vuppalanchi, R. (2012). Assessment and management of comorbidities (including cardiovascular disease) in patients with nonalcoholic fatty liver disease. Clinical Liver Disease, 1(4), 114–116. doi: 10.1002/cld.26.
Mitchenko, О. І., Romanov, V. Yu., Yanovska, K. O. Gelmedova, M. M., & Yakushko, L. V. (2011). Adypokiny ta yikh spivvidnoshennya u khvorykh z metabolichnym syndromom [Adipokins and their ratios in patients with metabolic syndrome]. Ukrainskyi kardiolohichnyi zhurnal, 6, 71–78. [in Ukrainian].
Ohashi, K., Ouchi, N., & Matsuzawa, Y. (2012). Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie, 94(10), 2137–2142. doi: 10.1016/j.biochi.2012.06.008.
Wild, S., Byrne, C., Tzoulaki, I., Lee, A., Rumley, A., Lowe, G., & Fowkes, F. (2009). Metabolic syndrome, haemostatic and inflammatory markers, cerebrovascular and peripheral arterial disease: The Edinburgh Artery Study. Atherosclerosis, 203(2), 604–609. doi: 10.1016/j.atherosclerosis.2008.07.028.
Matsuzawa, Y. (2010). Adiponectin: A Key Player in Obesity Related Disorders. CPD, 16(17), 1896–1901. doi: 10.2174/138161210791208893.
Babak, О. Ya., Kolesnikova, E. V., & Kravchenko, N. A. (2011). Moduliruyushchaya rol' adipocitokinov v razvitii nealkogol'noj zhirovoj bolezni pecheni [The modulating role of adipocytokines in the development of nonalcoholic fatty liver disease]. Ukrainskyi terapevtychnyi zhurnal, 2, 84–91. [in Ukrainian].
Menzaghi, C., Bacci, S., Salvemini, L., Mendonca, C., Palladino, G., Fontana, A., et al. (2013). Serum Resistin, Cardiovascular Disease and All-Cause Mortality in Patients with Type 2 Diabetes. PLoS ONE, 8(6), e64729. doi: 10.1371/journal.pone.0064729.
Marcy Silver, Y. (2013). Resistin Is a Novel Biomarker for a Risk of Heart Failure. Journal of Cardiovascular Diseases & Diagnosis, 01(04).
Kosygina, А. V. (2011) Adipocitokiny v nauchnoj i klinicheskoj praktike [Adipocytokines in research and clinical practice]. Ozhirenie i metabolizm, 1, 32–39. [in Russian].
Aleidi, S., Issa, A., Bustanji, H., Khalil, M., & Bustanji, Y. (2015). Adiponectin serum levels correlate with insulin resistance in type 2 diabetic patients. Saudi Pharmaceutical Journal, 23(3), 250–256. http://dx.doi.org/10.1016/j.jsps.2014.11.011.
Panchyshyn, J. М., Kondratuk, M. O., Guk-Leshnevska, Z. O., & Zenin, V. V. (2013). Chastota ozhyrinnia u khvorykh iz sertsevoiu nedostatnistiu [Prevalence of obesity in patients with heart failure]. Medychna hidrolohiia ta reabilitatsiia, 11(2), 63–67. [in Ukrainian].
Butrova, S. А. (2013). Ot e´pidemii ozhireniya k e´pidemii sakharnogo diabeta [From the obesity epidemic to epidemic of diabetes]. «Novosti mediciny i farmacii» Gastroe´nterologiya, 2, 19–24. [in Ukrainian].
Finelli, C. (2013). What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World Journal of Gastroenterology, 19(6), 802–12. doi: 10.3748/wjg.v19.i6.802.
Kovalova, J. О. (2010). Funktsionalnyj stan endoteliiu u khvorykh na stabilʹnu stenokardiiu z nadlyshkovoiu masoiu tila ta ozhyrinniam [Functional state of endothelium in patients with stable angina overweight and obesity]. Visnyk problem biolohii i medytsyny, 1, 143–146. [in Ukrainian].
Kravchenko, N. А., & Klimenko, N. N. (2012). Mekhanizmy razvitiya kardiometabolicheskogo sindroma pri ozhirenii [Mechanisms of development of cardio metabolic syndrome, obesity]. Problemy endokrynnoi patolohii, 1, 84–93. [in Ukrainian].
Teplyakov, A. T., Akhmedov, Sh. D., Suslova, T. Ye., Andriyanova, A. V., Kuznetsova, A. V., Protopopova, N. V., et al. (2015). Vliyaniye rezistora na techenie ishemicheskoj bolezni serdca u paciyentov s sakharnym diabetom 2-go tipa [Influence of resistin on the course of ischemic heart disease in patients with type 2 diabetes mellitus]. Byulleten' sibirskoj mediciny, 14(5), 73–82. [in Russian].
Sheng, C., Du, Z., Song, Y., Wu, X., Zhang, Y., Wu, M., et al. (2013). Human Resistin Inhibits Myogenic Differentiation and Induces Insulin Resistance in Myocytes. BioMed Research International, 2013, 1–8.
Tsochatzis, E., Papatheodoridis, G., & Archimandritis, A. (2009). Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy. Mediators of Inflammation, 2009, 1–8. doi: 10.1155/2009/831670.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
